LEARN ABOUT XIENCE AT 
EUROPCR MAY 16-19, 2017.

Visit the Abbott Booth

CLICK HERE

The Science Behind Xience Safety

XIENCE's unparalleled safety1-3 and superior performance is due to its unique design and fluoropolymer coating, as well as the elution of everolimus.

more

The Science Behind Xience Safety

XIENCE's unparalleled safety1-3 and superior performance is due to its unique design and fluoropolymer coating, as well as the elution of everolimus.

more

Xience Safety For Complex Patients

Multiple recent XIENCE trial results, with endpoints ranging from 1 to 3 years,4-7 reveal excellent safety data on stent thrombosis (ST) in left main disease, diabetes and other complex conditions.

more

Xience Safety For Complex Patients

Multiple recent XIENCE trial results, with endpoints ranging from 1 to 3 years,4-7 reveal excellent safety data on stent thrombosis (ST) in left main disease, diabetes and other complex conditions.

more

Experts' and Patient's point of view

From comparative testing of XIENCE

In testing thromboresistance: “We are finding that circumferential [polymer coatings] behave much better. But by far the best is XIENCE.”

Renu Virmani, MD

Play video

From comparative testing of XIENCE

In testing thromboresistance: “We are finding that circumferential [polymer coatings] behave much better. But by far the best is XIENCE.”

Renu Virmani, MD

Play video

From comparative testing of XIENCE

In testing thromboresistance: “We are finding that circumferential [polymer coatings] behave much better. But by far the best is XIENCE.”

Renu Virmani, MD

Play video

From comparative testing of XIENCE

In testing thromboresistance: “We are finding that circumferential [polymer coatings] behave much better. But by far the best is XIENCE.”

Renu Virmani, MD

Play video

Get the Latest Data

Sign up to receive the latest about XIENCE study results, as they become available.
  1. Valgimigli M. Effects of cobalt-chromium everolimus eluting or bare metal stent on fatal and non-fatal cardiovascular events: a patient-level meta analysis. EuroPCR 2014.  
  2. Bangalore S, et al. BMJ. 2013;347:f6625. doi: 10.1136/bmj.f6625.
  3. Palmerini T, et al. JACC. 2014;63:299-307. doi: 10.1016/j.jacc.2013.09.061.
  4. Stone GW, et al. EXCEL Trial 3-year data. N Engl J Med. 2016;375:2223-2235. doi: 10.1056/NEJMoa1610227.
  5. Teeuwen K, et al. PRISON IV Trial 1-year data. JACC Cardiovasc Interv. 2016. doi: 10.1016/ j.jcin.2016.10.017.
  6. Kaul U. 2-Year TUXEDO Outcomes. TCT 2016.
  7. Lam, M. TWENTE Trial. Am Heart J.  2015;169:69-77. doi: 10.1016/j.ahj.2014.10.011. 
  8. Palmerini T, et al. Lancet. 2012:379:1393-1402.

You are about to leave the Abbott family of websites for a third party website.

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.

The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit the website?

Disclaimer

Xiencestent.com is a product-specific website that is NOT intended for U.S. residents. This web content is exclusively reserved for health care professionals in countries with applicable health authority product registrations.

If you are a resident of a country other than those to which the site is directed, please contact your local Abbott affiliate to obtain the appropriate product information for your country of residence.

Do you wish to continue to visit the International section of this website?